cardiovascular%20disease%20prevention
CARDIOVASCULAR DISEASE PREVENTION
Patients 18 years old and above should receive a risk factor assessment for cardiovascular disease (CVD) at every routine physician visit.
Cardiovascular disease development is closely related to lifestyle characteristics and associated risk factors.
There is an overwhelming scientific evidence that lifestyle modifications and reduction of risk factors can slow the development of CVD both before and after the occurrence of a cardiovascular event.
Very high-risk group refers to patients with documented CVD, by invasive or non-invasive testing, and with presence of risk factors.
High-risk patients are those who have already experienced a cardiovascular event or have very high levels of individual risk factors.
Moderate-risk patients require monitoring of risk profile every 6-12 months.
Low-risk patients may be given conservative management, focusing on lifestyle interventions.
Drug Information

Indication: Co-administered w/ acetylsalicylic acid (ASA) for prevention of atherothrombotic events in adult patients w/ a...

Indication: Reduction of elevated total cholesterol (total-C), LDL-C, ApoB, the total-C: HDL-C ratio & triglycerides &...

Indication: Reduction of thrombotic CV events in patient w/ acute coronary syndrome who are to be managed w/ percutaneous ...

Indication: Adjunct to diet for the treatment of patients w/ elevated total & LDL cholesterol, apolipoprotein B & ...

Dosage: Adult ≥16 yr Temporary relief of minor aches & pains 1-6 tab every 4 hr. Max: 2.4 g daily. Acute MI 160

Cardin
aspirin + glycine

Indication: Transient ischaemic attacks, secondary prevention of MI. Prophylaxis against stroke, vascular occlusion & ...

Indication: Prophylaxis against strokes & heart attacks.

Indication: AMI. Prevention of heart attack in certain high-risk patients; prevention of CVA after transient ischaemic att...

Indication: Adult patients suffering from MI (few days until <35 days), ischaemic stroke (7 days until <6 mth) or es...

Indication: Prevention of atherothrombotic events in MI (from a few days until <35 days), ischaemic stroke (7 days unti...

1  /  6
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Mar 2016
Combination therapy with ezetimibe/statin improved low-density lipoprotein (LDL) cholesterol levels and cardiovascular outcomes in patients with acute coronary syndrome (ACS), as stated in a 16-week one-centre, prospective, randomised, open-label clinical trial.
13 Aug 2016
Prasugrel is superior than clopidogrel in the treatment of acute coronary syndrome (ACS) and ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) as presented in a study.
01 Mar 2016
Earlier oral β blocker administration is substantially correlated with lower rates of left ventricular (LV) dysfunction and in-hospital mortality in acute coronary syndrome patients, according to a study.
16 Dec 2018
The absence of the classical symptom of chest pain in patients with acute myocardial infarction (AMI) appears to be associated with more complications and higher short- and long-term mortality rates, particularly in younger and healthier patients, according to a study.